RxDoctor Payments Data

Tracy Manns

Psychiatric/Mental Health · Plymouth, INNPI 1326821026

Payments from drug & device makers

$732in general payments, 2019–2025

Across 30 payments — averaging $24.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$140
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$109
  • Neurocrine Biosciences, Inc.$70
  • Lundbeck LLC$60
  • Alkermes, Inc.$56
  • Supernus Pharmaceuticals, Inc.$55
  • plus $241 from 7 others

What the payments were for

  • Food & beverage$58279%
  • Education$15021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$732 in reported general payments places this provider in the 50th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$1,621
Medicare patients
21
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$151,786
Austedo XrDeutetrabenazine31$135,906
Invega SustennaPaliperidone Palmitate38$125,875
Invega TrinzaPaliperidone Palmitate11$125,512
VraylarCariprazine Hcl58$87,819
RexultiBrexpiprazole39$55,296
CaplytaLumateperone Tosylate20$37,327
AristadaAripiprazole Lauroxil11$35,094
TrintellixVortioxetine Hydrobromide45$32,668
Lurasidone Hcl130$13,952
Aripiprazole91$13,677
Fluphenazine Hcl20$7,567
Trazodone Hcl260$6,006
Quetiapine Fumarate ErQuetiapine Fumarate36$5,813
Desvenlafaxine Succinate ErDesvenlafaxine Succinate61$5,704

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$47$251,38749 claims
Neurocrine Biosciences, Inc.Ingrezza$70$151,78618 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$140$135,90631 claims
AbbVieVraylar$46$87,81958 claims
Otsuka America Pharmaceutical, Inc.Rexulti$47$55,29639 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$109$37,32720 claims
Alkermes, Inc.Aristada$56$35,09411 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$32,66845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Plymouth

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →